Tuesday, 19th September NSW State Cancer Conference 2023

Panel and Q&A facilitated by Dr Ursula Sansom-Daly – UNSW Sydney

Panellists: Professor Geoff Delaney AM – UNSW Sydney and South Western Sydney Local Health District and Dr Carolyn Mazariego – UNSW Sydney

INVITED SPEAKERS: PROF ROGER REDDELL & LOIS HOLLOWAY

• Progress towards clinical cancer proteomics - Roger Reddel
• Harnessing and learning from clinical practice data with data remaining at local institutions: The Australian Cancer Data Network - Lois Holloway

10:05AM - 10:45AM: Panel Discussion: Equitable access to precision medicine 

Professor Roger Reddel – Childrens Medical Research Institute

Dr Cassandra White – Calvery Mater

Professor Jennifer Martin – University of Newcastle

A/Professor Lois Holloway – Ingham Institute for Applied Medical Research

INVITED SPEAKERS: HUBERT HONDERMARK & HELEN RIZOS

• Cancer Neuroscience: a New Frontier in Oncology - Hubert Hondermarck
• Lessons from a decade of immune checkpoint inhibitors - Helen Rizos
• Identification of differential DNA methylation in phyllodes tumours establishes a signature of malignancy and delineates from metaplastic breast carcinoma - Braydon Meyer
• Putting the brakes on CDK4/6 inhibitor resistance in estrogen receptor positive breast cancers by harnessing the potential of CDK1 inhibition - Sarah Alexandrou
• More mutational sources underlying kataegis in African prostate cancer - Jue Jiang
• βIII-Tubulin knockdown sensitises pancreatic tumours to the tumour-specific death ligand TRAIL. - George Sharbeen
• Inhibition of the NPY signalling axis as a novel therapeutic option in Pancreatic Cancer. - Cecilia Chambers
• Using copper chelation to target epigenetic and kinase signalling influence of cell cycle in DIPG - Filip Michniewicz

INVITED SPEAKERS: CHRIS PAUL & ANDREA SMITH

• Best buys for behaviour change treatment during cancer care: Why, which ones and how? - Christine Paul
• Working together: perspectives of a consumer-researcher on metastatic cancer survivorship research and service delivery in Australia - Andrea Smith
• The Patient Experience of Pathways to Lung Cancer Diagnosis in Primary Care: a Mixed Methods Investigation of Factors Contributing to Diagnostic Delays in New South Wales, Australia. - Kimberley Mander
• Relative cancer survival in people with kidney failure: a population-based study in Australia and New Zealand 1980-2019 - Brenda Maria Rosales
• Mediators of changes in melanoma prevention and early detection behaviours in response to a genomic risk intervention in an Australian population sample - Amelia K Smit
• Mobile application of Gynecological Cancer Support (MGCS) program for women with gynecological cancer receiving chemotherapy in China：Multi-center randomized controlled trial - Jiemin Zhu
• Implementation study of a novel brief clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study) - Jia (Jenny) Liu
• Increased risk of rectal cancer and aggressive disease in sporadic early-onset colorectal cancer: a single site study of 3609 consecutive cases in NSW over 26 years from 1995 to 2020 - Ehsan Alvandi

INVITED SPEAKERS: PASCAL MANCUSO & LOUISE EMMETT

• Title to be confirmed - Pascal Mancuso
• PSMA theranostics: Where to Next? - Louise Emmett
• Comparing theory-based and non-theory-based implementation approaches to inform successful genomic medicine strategies in practice: a two-arm parallel randomised clinical trial for improving tumour testing and genetics services referral for Lynch syndrome. - Julia Steinberg
• Treatment response assessment with quantitative imaging biomarkers in prostate cancer treated with radiation and androgen deprivation therapy - Yu-Feng Wang
• Identifying synergistic combinations with the BCL2 inhibitor venetoclax for high-risk neuroblastoma - Joan Solomon
• Extracting Performance Status from Clinical Notes: Application Across Multiple Cancer Sites - Georgina Kennedy
• Perspectives of health professionals and patients on implementation of a predictive model of response to immunotherapies in advanced melanoma - Rehana A Salam
• Targeted delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment of childhood leukaemia. - Ernest Moles

• PI3K pathway inhibition augments PKC inhibitor response in uveal melanoma. - Sabine Abou Hamad
• Discovery of colorectal cancer diagnostic signatures using multi-omics. - Aziz AAA Alnakli
• Deciphering the exosomal RNA cargo involved in pancreatic cancer-related diabetes using transcriptomics: a novel approach for early detection of pancreatic cancer - Helen B Binang
• Differences in tumour infiltrating immune cells in BRCA1/BRCA2 mutant ovarian and breast cancer to predict response to immunotherapy - Michelle WY Brown
• Novel drug (CRO-67) in commercial pipeline have both anti-tumour and stromal reprogramming capacity - Shannon Chiang
• Alterations in the epigenetic machinery associated with prostate cancer health disparities - Jenna Craddock
• Therapeutic potential of the neurotrophin receptor p75^NTR in glioblastoma multiforme - Amiee AD Dowdell
• CD68 and chemokine CXCL16 expression in a cohort of primary and matched recurrent glioblastoma tumour samples. - Moira Graves
• Profiling small and large extracellular vesicles in prostate cancer cell lines using metabolomics for diagnosis and progression risk stratification - Mahmoud A Hamed
• Developing combination therapies with the FACT-inhibitor CBL0137 for diffuse midline glioma (DMG) - Holly Holliday
• Computational interrogation of telomere length and association with prostate cancer ancestral disparity - Ruotian Huang
• Suppression of the Cystine-Glutamate Transporter SLC7A11/xCT system enhances sensitivity of lung cancer cells to platinum-based drugs. - Anya Jensen
• Deconstructing a complex microenvironment with geometrically structured microtumours - Dr Chantel Kopecky
• Targeting Fibroblast Growth Factor (FGF)-fusions in previously untreatable cancers. - Hannah Law
• Investigation of modified glutamine transport via ASCT2 in Xenopus laevis oocytes.  - Vinitha M
• The use of Tissue Microarrays in cancer research – the pros and cons. - Kaylee O'Brien
• Temporal proteomic profiling reveals Nidogen-2 as a new stromal co-target in pancreatic cancer - Brooke Pereira
• Driver or passenger? Investigation of the T1010I MET mutation in a metastatic gastric cancer model - Ann-Katrin Piper
• Elucidating the Potential of DPR2b Aza BODIPY: A Novel Photosensitizer for Enhanced Photodynamic Therapy in Breast Cancer - RAJSHREE RAJINDRAN NAIR
• AhR and SULT1A1 induced bioactivation of highly selective breast cancer targeting molecules - Jennette A Sakoff
• MicroRNA to MicroRNA interactions: miR-21 regulation of miR17~92a cluster in Head & Neck Squamous Cell Carcinoma - Sarah Stapleton
• Robotic-Assisted Radical Prostatectomy on a Patient With Large Mullerian Duct Cyst - Jacob Bird
• Repurposing pirfenidone in combination with temozolomide for the treatment of glioblastoma - Mahsa MV Vaez Zadeh
• The microbial landscape at the gut mucosa in early-stage bowel polyps. - Zoe M Welham
• Evaluation of novel therapies targeting the p53 and apoptotic pathways in treatment-resistant estrogen receptor-positive breast cancer   - Fiona H Zhou
• Relationships between tumour microenvironment composition in keratinocyte cancers from organ transplant recipients and clinicopathological parameters - Catherine Zilberg
• Activating the endogenous armoury: anticancer drugs as immunotherapy enablers - Hieu Nguyen
• Serum and Tissue Metallomics in Pancreatic Ductal Adenocarcinoma as Potential Diagnostic and Prognostic Biomarkers - Sooin Byeon
• Screen-reading volume using artificial intelligence (AI) in breast cancer screening - Luke Marinovich
• Understanding diagnostic performances of surgical trainees on digital mammograms: A comparison to radiology trainees via BREAST test set - Jayden Wells
• Epithelial ovarian cancer survival by demographic factors in New South Wales: Analysis of data from The Enduring Cancer Data Linkage program - Saima Islam
• Projecting the future Australian epithelial ovarian cancer burden by histological subtype. - Kirstie McLoughlin
• Causal inference and mediation methods in randomised controlled trials: a methodological scoping review - Ellie Medcalf
• Alcohol consumption, drinking patterns and cause-specific mortality in an Australian cohort of 180,575 participants aged 45 years and over. - Peter Sarich
• Embedding equity into routine collection of patient reported measures - Sandra Avery
• Medical Imaging Simulated Radiation Therapy - improving access to palliative Radiation Therapy in WNSWLHD - Zoe Clarke
• Is that drug listed on the Pharmaceutical Benefits Scheme (PBS)? - Sharon M Leadbitter
• Adapting Radiation Oncology to Rural and Regional communities - Catherine Osborne
• Protocol for a pilot study to explore opportunities to recruit Culturally and Linguistically Diverse participants to research - Christine Paul
• Tumour characteristics and outcomes of gastric and oesophageal cancers in culturally and linguistically diverse (CALD) patients treated with curative intent in South Western Sydney - Robert Yoon
• Building research capacity to enhance care and outcomes for patients with head and neck cancer: The AlliEd Health and Nursing Head And Neck CancEr (ENHANCE) Research Group Experience - Merran Findlay
• Evaluation of a consumer engagement model used in a cancer research network  - Stella Jun
• Estimating survival scenarios in patients with advanced oesophageal and gastric (AOG) adenocarcinoma treated with systemic therapy: A systematic review of randomised-controlled trials (RCT). - Sayeda Dr Naher
• A method for correlating preclinical MRI with histopathology using a fiducial marker system - William S Price
• Cost estimation of radiotherapy for local control and overall survival benefit of selected cancers in the pelvic region: Rectal cancers and cervical cancers - Jesmin Shafiq
• Measuring the environmental impact of robotic surgery: A literature review - Jacob Bird
• Embracing diversity in engaging the community in clinical trials with ConViCTioN - Vanessa Yenson
• Systematic review of methodological conduct and risk of bias of Head and Neck cancer outcome prediction models, with recommendations for clinical practice. - Farhannah Aly
• Are we starting with Normal Skeletal Muscle and Fat mass measures for men commencing Androgen Deprivation Therapy? - Suzzanna Fettell
• Taming the Immune Response: CRISPR Based Knockout of HLA Class I and II to Prevent Allorejection of Off-the-Shelf Chimeric Antigen Receptor T-cells - Melanie Mach
• Detection of spatially-resolved cell-cell interaction across cancer tissue sections - Minh Tran
• Enhanced Diagnostic Efficacy in Breast Radiology Education via Artificial Intelligence: A Preliminary Study - Phuong D (Yun) Trieu
• Are measures and related symptoms of cachexia recorded as outcomes in gastrointestinal cancer chemotherapy clinical trials? - Ross Valaire
• Factors affecting patient compliance and acceptability of medicinal cannabis use for symptom relief in an Australian cancer care setting - Jennifer Ong
• More than just single nucleotide alterations: Delving into the genome of paediatric cancer predisposition - Safaa Al Haj Hussein
• Encyclopedic tumour analysis based personalised combination regimens improves patient outcomes in advanced and refractory solid cancer - Joachim Fluhrer
• Utilizing multi-omics technologies to examine the potential role of causative pathogens in glioblastoma. - Bavani Gunasegaran
• Informing health system planning for biomarker-based treatment: projections of cancer prevalence to 2042 for key pan-tumour biomarkers (dMMR, MSI, high TMB) - Yoon-Jung Kang
• Integrated single cell analysis of chemical and genetic HDAC inhibition to rationalise treatment for neuroblastoma patients - Monica Phimmachanh
• TIM3-targeting chimeric antigen receptor T-cells for treating acute myeloid leukaemia - Daochen Tong
• Cancer prehabilitation: research priorities of patients and carers - a qualitative study - Jennifer K Vu
• Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in a cohort of patients with advanced ovarian cancer - Bonnita Werner
• An Evaluation of Brain Tumour Information Resources: Current State and Next Steps. - Thomas Carlick
• Survivors of childhood cancer experiences of bullying on return to school and work - Joanna Fardell
• Can interactive online education modules improve family carer engagement in cancer care? Evaluation of the eTRIO program among oncology health professionals, patients, and carers. - Rebekah Laidsaar-Powell
• iCanBlend: Blended psychological therapy for the treatment of anxiety and depression in adult patients with an experience of cancer. - Kelly F Nunes-Zlotkowski
• Do young people who survive cancer, identify as ‘survivors’? Prevalence and predictors of cancer-related identities among adolescents and young adults following cancer - Ursula Sansom-Daly
• Caregiver fear of cancer recurrence levels, measures, and associations: a systematic review and meta-analysis   - Kyra Webb
• Patterns of care and outcomes for a clinical cohort of patients with lung cancer (2016-2021): Report on the Embedding Research (and Evidence) in Cancer Healthcare - EnRICH Program - Bea Brown
• Screening participant and health service impact of population-based breast density notification in Australia: protocol for a co-designed randomised controlled trial - Brooke Nickel
• Adherence in randomised clinical trials of melanoma early diagnosis: a scoping review. - Deonna Ackermann
• Acceptability of risk-tailored cancer screening in the population: multilevel stakeholder perspectives - Kate L.A Dunlop
• Combining effective interventions to increase bowel cancer screening equitably. - Stephanie SW Walker
• The impact of breast density notification on culturally and linguistically diverse (CALD) women – A systematic review - Jennifer Isautier
• Impact of an Online Risk Prediction Tool for Sentinel Node Positivity on Clinical Decision Making in Melanoma Care: A Mixed Methods Study - Rehana A Salam
• Global radiomic features from mammography for predicting difficult‑to‑interpret normal cases - Somphone Siviengphanom
• Neurofilament Light Chain in Axonal Degeneration in Paclitaxel Induced Peripheral Neurotoxicity - Masarra MD Al Deleemy
• The clinically active PARP inhibitor Olaparib ameliorates Doxorubicin-induced Cardiotoxicity in both in vitro and In vivo model - Dongqing Kelly Chen
• SUppoRting PAtient-centred SurvivorShip (SURPASS) at St Vincent’s Health Network: adaptation and adoption of the ‘My Personal Plan’ prostate cancer survivorship care plan for generic use: A study protocol - Nicola R Fearn
• Carfilzomib-induced cardiotoxicity: mechanisms & potential treatments. - Tatt Jhong Haw
• Mechanistic insight of chemotherapy-induced cardiotoxicity: elucidating common pathways for various chemotherapeutic drug classes. - Conagh C.K. Kelly
• Examining the current state of supportive care for colorectal cancer survivors in general practice settings - Bora Kim
• Cross-cultural adaptation of the Breast Cancer and Lymphedema Symptom Experience Index (BCLE-SEI) in Hindi - Vincent Singh Paramanandam
• Cross-cultural adaptation of the Breast Cancer and Lymphedema Symptom Experience Index (BCLE-SEI) in Bengali - Vincent Singh Paramanandam
• Change in health-related quality of life after a cancer diagnosis in a large cohort of Australian women. - Md Mijanur Rahman
• Physical activity interventions for cancer survivors in Australian general practice: Realist review - Matthew Patrio MPS Sugiarto
• Prevalence of Australians exposed to potentially cardiotoxic cancer medicines - Claire Vajdic
• Chemotherapies and effects on cardiomyocyte viability: which drugs are directly cardiotoxic? - Lohis Balachandran
• Implementation of a Bone Marrow Sparing Planning Technique for Extended-Field Gynaecological Radiation Therapy  - Gemma Busuttil
• Anti-Cancerous effect of novel chlorambucil-platinum(IV) prodrugs against triple negative breast cancer cells through multi-mechanistic pathways, including changes in the organization of the microtubule cytoskeleton - Maria George 1 Elias
• Deep QSM - Identification of gold seed fiducial markers for MRI only treatment planning in radiation therapy - Jonathan Goodwin
• Outcome heterogeneity in prehabilitation trials- should we be worried? - Wilson Jiang
• In-vitro evaluation of a ROR1 targeting antibody drug conjugate in high grade serous ovarian cancer - Dongli Liu
• Inhibition of ATR synergistically enhances cell death in combination with temozolomide, radiation and lomustine in glioblastoma cells - Mathew Lozinski
• The effect of exercise interventions on hospital length of stay and admissions during cancer treatment: a systematic review and meta-analysis - David Mizrahi
• Atovaquone Radiosensitises Diffuse Midline Gliomas by Inhibiting Mitochondrial Metabolism and Hypoxia - Faiqa Miss Mudassar
• Trends in breast cancer treatment in Australia from 2006 to 2019 - Lara Petelin
• Using Metabolic ketosis to alter DNA Damage response and Cellular Senescence pathways during chemotherapy in Acute Leukemia patients - Gayathiri Rajakumar
• A case of Immune checkpoint inhibitors related tubulo-interstitial nephritis in a metastatic melanoma patient with multiple immune-related adverse events - Joy Samuel
• Decision Regret in Patients After Robotic or Laparoscopic Radical Prostatectomy - A Literature Review - Jacob Bird
• Uncovering the druggable proteome of Paediatric Diffuse Midline Gliomas (DMGs) using a chemoproteomic approach.  - Joshua JZ Zhu

INVITED SPEAKER: JOHN CONNOLLY

• Participation in a mammographic screening program for women with intellectual disability: A population-based retrospective cohort study - Janelle Weise
• Targeting Urokinase Plasminogen Activator Combined with Gemcitabine Enhances Immune Regulation and Inhibits Metastasis in Pancreatic Cancer - S M Zahid HOSEN
• Single cell analysis assigns key roles to cellular plasticity and distinct DNA repair signatures in platinum-resistant ovarian cancer cells - Naisana Seyedasli
• Impact of artificial intelligence-enabled therapy decision support on a nationwide molecular tumour board: preliminary findings of a before-after implementation study - Frank P Lin
• Transcriptomic patterns associated with the development of immune-related adverse events. - Dmitrii Shek
• Short-term effects of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0-II) melanoma. - Jake R Thompson
• Understanding cardiac risk in thoracic cancer radiotherapy - Vicky Chin
• Title to be confirmed - John Connolly